Meeting
2017 ASCO Annual Meeting
CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).
Authors
Eve Maubec
AP-HP, Hôpital Avicenne, Bobigny, France
Eve Maubec , Sabine Helfen , Isabelle Scheer-Senyarich , Marouane Boubaya Sr., Olivier Schischmanoff , Céline Alloux , Lydia Deschamps , Peter Petrow , Isabelle Lopez , Annick Tibi , Vincent Levy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02883556
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS9596)
DOI
10.1200/JCO.2017.35.15_suppl.TPS9596
Abstract #
TPS9596
Poster Bd #
201b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.
First Author: Dean F. Bajorin
Poster
2020 ASCO Virtual Scientific Program
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
First Author: Nataliya Mar
Poster
2016 Gastrointestinal Cancers Symposium
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
First Author: Charles S. Fuchs
Poster
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
First Author: Christos Chouaid